Is LifePoint Health (LPNT) A Great Stock For Value Investors?

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value?

One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process. Let’s put LifePoint Health, Inc. (NASDAQ:LPNT) stock into this equation and find out if it is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks:

PE Ratio

A key metric that value investors always look at is the Price to Earnings Ratio, or PE for short. This shows us how much investors are willing to pay for each dollar of earnings in a given stock, and is easily one of the most popular financial ratios in the world. The best use of the PE ratio is to compare the stock’s current PE ratio with: a) where this ratio has been in the past; b) how it compares to the average for the industry/sector; and c) how it compares to the market as a whole.

On this front, LifePoint has a trailing twelve months PE ratio of 17.17, as you can see in the chart below:

This level actually compares pretty favorably with the market at large, as the PE for the S&P 500 compares in at about 20.30. If we focus on the stock’s long-term PE trend, the current level puts LifePoint’s current PE ratio below its midpoint over the past five years.

Further, the stock’s PE also compares favorably with the Zacks classified Medical Care industry’s trailing twelve months PE ratio, which stands at 18.03. At the very least, this indicates that the stock is relatively undervalued right now, compared to its peers.

We should also point out that LifePoint has a forward PE ratio (price relative to this year’s earnings) of just 15.32, so it is fair to say that a slightly more value-oriented path may be ahead for LifePoint stock in the near term too.

P/S Ratio

Another key metric to note is the Price/Sales ratio. This approach compares a given stock’s price to its total sales, where a lower reading is generally considered better. Some people like this metric more than other value-focused ones because it looks at sales, something that is far harder to manipulate with accounting tricks than earnings.

Right now, LifePoint has a P/S ratio of about 0.42. This is far lower than the S&P 500 average, which comes in at 3.14 right now. Also, as we can see in the chart below, this is well below the highs for this stock in particular over the past few years.

If anything, LPNT is in the lower end of its range in the time period from a P/S metric, suggesting some level of undervalued trading—at least compared to historical norms.

Broad Value Outlook

In aggregate, LifePoint currently has a Zacks Value Style Score of ‘A’, putting it into the top 20% of all stocks we cover from this look. This makes LifePoint a solid choice for value investors.

What About the Stock Overall?

Though LifePoint might be a good choice for value investors, there are plenty of other factors to consider before investing in this name. In particular, it is worth noting that the company has a Growth grade of ‘A’ and a Momentum score of ‘C’. This gives LPNT a Zacks VGM score—or its overarching fundamental grade—of ‘A’. (You can read more about the Zacks Style Scores here >>)

Meanwhile, the company’s recent earnings estimates have been mixed at best. The current quarter has seen one estimate going higher in the past sixty days compared to eight lower, while the full year estimate has seen seven upward and three downward movements in the same time period.

This has had just a small impact on the consensus estimate though as the current quarter consensus estimate has fallen by 3.2% in the past two months, while the full year estimate has inched lower by 0.5%. You can see the consensus estimate trend and recent price action for the stock in the chart below:

LifePoint Health, Inc. Price and Consensus

LifePoint Health, Inc. Price and Consensus | LifePoint Health, Inc. Quote

This somewhat mixed trend is why the stock has just a Zacks Rank #3 (Hold) and why we are looking for in-line performance from the company in the near term.

Bottom Line

LifePoint is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front. However, with a sluggish industry rank (Bottom 22% out of more than 250 industries) and a Zacks Rank #3, it is hard to get too excited about this company overall. In fact, in last one year, the Zacks Medical care industry has clearly underperformed the broader industry.

So, value investors might want to wait for estimates, analyst sentiment and broader factors to turn around in this name first, but once that happens, this stock could be a compelling pick.

Looking for Stocks with Skyrocketing Upside?

Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.

Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>